Who we are

Owen Mumford specialises in integrated design and build services from a broad range of self-injection platform devices for the pharmaceutical industry.

From the first automatic lancing device to our patented self-injection devices, with Owen Mumford you have access to unrivalled experience in designing, developing and delivering solutions to help you make adherence easier for patients.


With more than 65 years’ experience, your device is in trusted hands with Owen Mumford.

From day one, we will guide you throughout the development process; at every step, you will benefit from professional and supportive project management, processes, industrialisation and production for a smooth development and launch.

The springless, passive safety device for pre-filled syringes

Fully designed, developed and ready for commercial supply

Comfort

Large, ergonomic plunger head and a smooth, integrated finger flange, resulting in an integrated look and feel.

Secure plunger

Plunger cannot detach when removing the RNS.

Reduced risk

No compromise to sterility in assembly – plunger does not touch the bung.

User confidence

Syringe barrel is unobscured, allowing the user to check the contents of the syringe, and to confirm the full dose has been delivered.

Reliability

Prevention of occidental activation e.g. in transit.

Simple 2-step final sembly

Final assembly process is simple and outside of the sterile filling area.

Cost effective

Designed to work with standard, pre-filled syringes which means no change to existing primary container and minimises training costs.

Passive safety

Passive needle retraction means that the device is safe as soon as the plunger is fully depressed

Self-Injection Device Solutions 

Ensuring that patients are willing and able to inject their medication is key to their well-being. As pioneers in self-injection technologies, our experience enables us to effectively work with you to find the right drug delivery solution.


Please visit: omdevicesolutions.com

Go to article: Home | The absence of antivenomGo to article: In this issueGo to article: Daiichi JitsugyoGo to article: ContentsGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: The pharma industry briefingGo to article: TSS Company InsightGo to article: TSS ABGo to article: Action Medical Research: celebrating decades of discovery Go to article: Swiss WorldCargoGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Moehs Iberica SLGo to article: Owen MumfordGo to article: How government policy has shaped China’s pharma phenomenonGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Novo NordiskGo to article: Snake venom in pharma; access to antivenom is a topic that needs attentionGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: ME Logistic ServicesGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Aseptic TechnologiesGo to article: False flags: are search engines benefiting rogue online pharmacies?Go to article: CBDepot Company InsightGo to article: CBDepotGo to article: Wilco Company Insight Go to article: WilcoGo to article: The Mighty: how patients and pharma align in the age of social media Go to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: MicronovaGo to article: Inside Italy’s pharmaceutical industry Go to article: KlingeGo to article: BEAGo to article: Erdmann Design SwitzerlandGo to article: Inside the UK’s first vaccines innovation centreGo to article: AralabGo to article: Applikon BiotechnologyGo to article: BaxterGo to article: NymiGo to article: Fostering closer collaboration between manufacturing & regulatory functionsGo to article: EmisphereGo to article: SephaGo to article: Contract Pharmaceuticals Limited CanadaGo to article: EventsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Next issueGo to article: PolpharmaGo to article: BioAdvice